Jazz Pharmaceuticals
JAZZ
230.26
-6.19
-2.62%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
230.26
-6.19
-2.62%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
- Total institutional ownership fell 1.2 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 102.93% -1.21pp
- Institutions
- 815 -4
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund84.19%
Hedge Fund10.70%
Individual/Insider2.95%
Public Company2.57%
Government Pension Fund1.65%
Private Company1.05%
Sovereign Wealth Fund1.05%
VC/PE Fund0.89%
Insurance Company0.41%
Top holders as of 2026-09-30
BlackRock
10.06% · 6.45M sh
FMR
8.57% · 5.50M sh
Vanguard Capital Management, LLC
5.01% · 3.21M sh
Vanguard Portfolio Management, LLC
4.79% · 3.07M sh
Capital Research
3.73% · 2.39M sh
LSV Asset Management
3.33% · 2.14M sh
State Street Global Advisors
3.22% · 2.07M sh
Franklin Resources
3.03% · 1.94M sh
Geode Capital Management, LLC
2.39% · 1.53M sh
Fuller & Thaler Asset Management, Inc.
2.55% · 1.64M sh
Dimensional Fund Advisors
2.26% · 1.45M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Seamus Mulligan | Independent Director | 2.00% |
| Bruce Cozadd | Chairperson | 0.50% |
| Renee Gala | Chief Executive Officer | 0.08% |
| Kenneth O’Keefe | Former Independent Director | 0.04% |
| Robert Iannone | Executive VP, Chief Medical Officer and Global Head of Research & Development | 0.04% |
| Philip Johnson | Chief Financial Officer | 0.04% |
| Samantha Pearce | Executive Vice President | 0.03% |
| Neena Patil | Chief Legal Officer | 0.03% |
| Patrick Gerald Enright | Independent Director | 0.03% |
| Heather McSharry | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Bruce Cozadd | Chairperson | Derivative Exercise and Sale | -68,808 | $136.18–237.39 |
| 2026-11-05 | Bruce Cozadd | Chairperson | Derivative Exercise and Retained | +17,692 | $136.18 |
| 2026-11-03 | Patricia Carr | Chief Accounting Officer | Open Market Disposition | -163 | $231.27 |
| 2026-11-03 | Patricia Carr | Chief Accounting Officer | Derivative Exercise and Sale | -1,250 | $140.03–231.37 |
| 2026-11-02 | Renee Gala | Chief Executive Officer | Automatic Disposition | -1,000 | $225.37 |
| 2026-11-01 | Bruce Cozadd | Chairperson | Automatic Disposition | -6,000 | $215.84 |
| 2026-10-07 | Anne O'Riordan | Former Independent Director | Intent to Sell (Form 144) | -14,687 | $228.55 |
| 2026-10-05 | Renee Gala | Chief Executive Officer | Automatic Disposition | -2,000 | $236.40 |
| 2026-09-30 | Bruce Cozadd | Chairperson | Automatic Disposition | -6,000 | $230.33 |
| 2026-09-09 | Neena Patil | Chief Legal Officer | Automatic Disposition | -1,200 | $240.94 |
| 2026-09-07 | Renee Gala | Chief Executive Officer | Sale to Issuer | -1,967 | $246.81 |
| 2026-09-07 | Renee Gala | Chief Executive Officer | Automatic Disposition | -2,000 | $243.03 |
| 2026-09-07 | Mary Henderson | Senior Vice President of Technical Operations | Sale to Issuer | -1,427 | $241.20–243.03 |
| 2026-08-31 | Bruce Cozadd | Chairperson | Automatic Disposition | -6,000 | $250.13 |
| 2026-08-30 | Bruce Cozadd | Chairperson | Sale to Issuer | -1,219 | $241.39–244.06 |
| 2026-08-30 | Norbert Riedel | Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Ted Love | Independent Director | Sale to Issuer | -743 | $241.39–244.06 |
| 2026-08-30 | Patrick Gerald Enright | Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
| 2026-08-30 | Patrick Kennedy | Independent Director | Sale to Issuer | -1,855 | $241.39–244.06 |
| 2026-08-30 | Rick Winningham | Lead Independent Director | Sale to Issuer | -1,706 | $241.39–244.64 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.
Jazz Pharmaceuticals discussion 0 comments